NCT02622243View on ClinicalTrials.gov

Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Asthma
Interventions
DRUG

Tiotropium

long acting muscarinic antagonist

DRUG

glycopyrronium

long acting muscarinic antagonist

DEVICE

Respimat

inhaler device used to deliver active tiotropium or placebo

DEVICE

Breezehaler

inhaler device used to deliver active glycopyrronium or placebo

Trial Locations (1)

S7N 0W8

Asthma Research Lab, Saskatoon

All Listed Sponsors
lead

University of Saskatchewan

OTHER

NCT02622243 - Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge | Biotech Hunter | Biotech Hunter